6Y4 Stock Chart & Stats
€0.97
-€0.02(-2.26%)
At close: 4:00 PM EDT
€0.97
-€0.02(-2.26%)
Day’s Range― - ―
52-Week Range€0.81 - €1.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€238.64M
Enterprise Value€2.64K
Total Cash (Recent Filing)€905.64M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.36Price Target Upside245.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€438.39K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEffectively no debt reduces solvency and refinancing pressure while preserving financial flexibility for clinical development. The sizable equity base provides a buffer against near-term obligations, although continued losses could reduce that protection over time.
Recent Revenue GrowthAlthough the revenue base remains small, positive TTM growth indicates some increase in recognized business activity. If this trend develops alongside successful clinical progress, it could provide an early foundation for future commercialization or partnership-related income.
Focused Clinical PipelineVicore has a defined therapeutic focus in severe lung disease, centered on a lead candidate and a specific high-need indication. Concentrating resources around buloxibutid can support clearer clinical execution and potential value creation if development succeeds.
Bears Say
Severe Ongoing LossesThe scale of continuing losses shows that the business has not yet reached economic self-sufficiency. Persistent negative profitability can erode the equity base, constrain investment choices, and require successful development outcomes before durable earnings become possible.
Heavy Cash BurnLarge and still deteriorating cash outflows increase dependence on future financing, partnerships, or a meaningful revenue step-up. This creates ongoing funding and dilution risk and may limit the company’s ability to sustain development without additional capital.
No Established Commercial Revenue BaseVicore remains dependent on advancing candidates through clinical development rather than established product sales. Until approval and commercialization occur, revenue visibility is structurally limited and financial support must come mainly from funding, grants, or potential partnering.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.81 and its highest was €1.86 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €238.64M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Nov 05, 2026 which is in 36 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on Aug 21, 2026. The company reported -€0.046 earnings per share for the quarter, missing the consensus estimate of -€0.037 by -€0.009.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.046 in its last earnings report, missing expectations of -€0.037. Following the earnings report the stock price went down -3.063%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
6Y4 Stock 12 Month Forecast
Average Price Target
€3.36
▲(245.91% Upside)
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Cantargia AB
―